Sign in
Taking peoplePhase 3

International study on RD03/2016 eye drops compared to Leviosa® eye drops for the prevention and treatment of inflammation and the prevention of infections associated with cataract surgery in adults – FAST 7

Key facts

Who runs it
Ntc S.r.l.
Where
Greece, Italy, Poland, Spain, and Sweden28 sites in 5 countriesChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
536 people, planned
Started
1 Sept 2026
Expected to end
31 Dec 2026
Type of study
Interventional
Record updated
13 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Signed written informed consent must be obtained before any assessment is performed
  • Male or female, age ≥40 years
  • Scheduled senile or presenile cataract surgery (not yet performed)
  • Willing to interrupt the use of contact lenses for the entire duration of the study
  • Able and willing to follow study procedures
  • For females of childbearing potential, the use of highly effective contraception and agreement to use such a method during study participation
  • Cataract surgery completed without complications

Who cannot take part

  • Participation in previous clinical studies if less than 5 half-lives of the IMPs used have not elapsed
  • Patients undergoing bilateral cataract surgery
  • Patients under treatment with prostaglandin analogues or intravitreal injections of anti-VEGF (vascular endothelial growth factor) drugs
  • Ocular surgery in the study eye (including laser surgery) in the 3 months before screening
  • Contraindication to ocular treatment with ketorolac, dexamethasone or levofloxacin as follows: - Herpes simplex keratitis, vaccinia, varicella and other viral diseases of the cornea and conjunctiva - Fungal and mycobacterial diseases of ocular structures or untreated parasitic eye infections - Uncontrolled intraocular hypertension - Uncontrolled glaucoma - Untreated purulent infections of the eye - Acute, untreated bacterial infections
  • Ocular conditions that at the discretion of the Investigator may interfere with the efficacy and/or safety evaluations (e.g. ocular herpes, blepharitis, conjunctivitis, uveitis, keratitis, diabetic retinopathy, retinal vein occlusions, retinal vasculitis, retinal angiomatous proliferation, pseudo-exfoliation syndrome, intraoperative floppy iris syndrome, etc.)
  • Hypersensitivity to the products or their excipients
  • Systemic diseases that may interfere with the results of the study (e.g. rheumatoid arthritis, Sjögren's syndrome, Behçet's disease, systemic lupus erythematosus, scleroderma with major ocular involvement, etc.)
  • Any condition that could interfere with the correct instillation of eye drops
  • Pregnancy or breastfeeding
  • Monocular patients
  • Visual Acuity < 20/80 of the contralateral eye measured as ETDRS or Snellen 20 feet, equal to 0.25 in decimal

This trial has no sites in United States.

It has sites in 5 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

To demonstrate the non-inferior efficacy of RD03/2016 vs. Leviosa® for 7 days in the prevention and treatment of postoperative ocular inflammation.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Multicenter, randomized, double-blind, parallel-group clinical study comparing RD03/2016 (levoFloxacin and ketorolac trometAmol) eye drops vs Leviosa® (levofloxacin and dexamethaSone 21-phosphaTe) eye drops for 7 days for the prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults. (FAST 7)
Record updated
13 November 2026